Stock Detail
ONYX PHARMACEUTICALS INC
Drugs
ONXX @ Yahoo Finance | ONXX Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $38.39 | $39.39 | $-0.67 | -1.72% | 0.00 | $39.06 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $38.65 | $38.23 | 645,299 | 2.44B | 1.11M | -15.42 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 39.83 | 39.11 | 38.67 | 37.95 | 37.51 |
Stock Profile
Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of small molecule drugs for the treatment of cancer. Its primary product includes sorafenib, a Phase III orally available signal transduction inhibitor, inhibits proliferation of cancer cells and angiogenesis. In addition, sorafenib inhibits VEGFR-2 and PDGFR-ß, two proteins involved in angiogenesis, and other proteins that might be implicated in cancer. The company also develops PD 332991, a Phase I clinical trial product, a small molecule cell cycle inhibitor targeting a cyclin-dependent kinase. Onyx Pharmaceuticals has collaboration agreement with Bayer Pharmaceuticals Corporation to discover, develop, and market compounds that inhibit the function, or modulate the activity, of the RAS signaling pathway to treat cancer and other diseases. The company was established in 1992 and is headquartered in Emeryville, California.